Literature DB >> 12092743

Toxicity of high-dose carboplatin: ultrafiltered and not total plasma pharmacokinetics is of clinical relevance.

Charlotte Kloft1, Wolfgang Siegert, Joerg Beyer, Ulrich Jaehde.   

Abstract

Combination chemotherapy containing high-dose carboplatin is a therapeutic option for patients with poor-risk germ cell tumors. Since such treatment is relatively toxic, pharmacokinetic characteristics of total and ultrafiltered platinum, representing different species of platinum complexes formed, were investigated in 29 patients in relation to toxicity. The goodness-of-fit parameters revealed that a two-compartment model with weighting (1/C2i) resulted in the best fit. The terminal half-life of total platinum > 5 days was fourfold longer than that of ultrafiltered platinum, indicating long-term retention. At stem cell rescue, an ultrafiltered concentration of < or = 0.223 microg/ml did not impair hematological recovery. Ultrafiltered but not total platinum concentrations or AUC values were significantly correlated to an increase in creatinine concentration and different types of toxicity associated with high-dose treatment. Since the fraction unbound is time dependent and highly variable among patients, measuring ultrafiltered concentrations is highly recommended as they represent the clinically relevant platinum complexes in high-dose treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12092743     DOI: 10.1177/009127002401102704

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  6 in total

1.  Hematological toxicity of carboplatin for gynecological cancer according to body mass index.

Authors:  Fernando Gutierrez; Guillermo Antonio Gonzalez-de-la-Fuente; Gloria Julia Nazco; Juana Oramas; Norberto Batista
Journal:  Eur J Clin Pharmacol       Date:  2016-06-10       Impact factor: 2.953

2.  Toxicity and cerebrospinal fluid levels of carboplatin chronically infused into the brainstem of a primate.

Authors:  R J Strege; Y J Liu; A Kiely; R M Johnson; E M Gillis; P Storm; B S Carson; G I Jallo; M Guarnieri
Journal:  J Neurooncol       Date:  2004-05       Impact factor: 4.130

3.  Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.

Authors:  G J Veal; J Errington; M J Tilby; A D J Pearson; A B M Foot; H McDowell; C Ellershaw; B Pizer; G M Nowell; D G Pearson; A V Boddy
Journal:  Br J Cancer       Date:  2007-02-13       Impact factor: 7.640

4.  Abdominal tissue concentrations and penetration of carboplatin in a HIPEC procedure ‒ assessment in a novel porcine model.

Authors:  Elisabeth K Petersen; Mats Bue; Christina Harlev; Andrea R Jørgensen; Anne Schmedes; Pelle Hanberg; Lone K Petersen; Maiken Stilling
Journal:  Pleura Peritoneum       Date:  2022-06-06

5.  Comparative Pharmacokinetics and Allometric Scaling of Carboplatin in Different Avian Species.

Authors:  Gunther Antonissen; Mathias Devreese; Siegrid De Baere; Tom Hellebuyck; Isabel Van de Maele; Lieze Rouffaer; Hendrickus J J Stemkens; Patrick De Backer; An Martel; Siska Croubels
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

6.  Individualised dosing strategy for high-dose carboplatin in patients with germ cell cancer.

Authors:  C Kloft; W Siegert; U Jaehde
Journal:  Br J Cancer       Date:  2003-09-01       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.